Britannia Life Sciences Inc.
BLAB.CNCNQHealthcare● Active
$0.09
+$0.00(+0.00%)
Market Cap$13791619
P/E Ratio—
52W High$0.14
52W Low$0.06
Britannia Life Sciences Inc. (BLAB.CN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BLAB.CN · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.37M | $7.57M | $6.40M | $7.30M | $1.42M |
| Cost of Revenue | $0.34M | $2.72M | $1.77M | $2.04M | $0.25M |
| Gross Profit | $0.03M | $4.85M | $4.64M | $5.26M | $1.17M |
| Gross Margin %(computed) | 7.40% | 64.12% | 72.43% | 72.08% | 82.24% |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| G&A Expenses | $1.99M | $3.24M | $3.40M | $13.43M | $0.75M |
| Total Operating Expenses | $2.28M | $4.68M | $4.46M | $4.88M | $1.06M |
| Operating Income | ($2.25M) | $0.17M | $0.18M | $0.38M | $0.11M |
| Operating Margin %(computed) | -609.28% | 2.29% | 2.78% | 5.20% | 8.06% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.11M | $1.28M | $0.85M | $2.31M | $0.36M |
| Income Before Tax | ($4.56M) | ($4.47M) | $5.86M | ($13.27M) | $0.40M |
| Income Tax Expense | $0.00M | ($0.07M) | $0.02M | $0.71M | $0.26M |
| Net Income | $7.39M | ($4.77M) | $5.08M | ($15.46M) | ($0.16M) |
| Net Margin %(computed) | — | -62.99% | 79.39% | -211.76% | -11.03% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.03 | $-0.03 | $0.03 | $-0.14 | $-0.00 |
| Wtd Avg Shares | 162.25M | 162.25M | 162.14M | 109.50M | 76.75M |
| EBITDA | ($4.39M) | ($1.90M) | $6.95M | ($10.77M) | ($1.62M) |
| EBITDA Margin %(computed) | — | -25.05% | 108.61% | -147.55% | -113.54% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · CAD · M
Explore more Britannia Life Sciences Inc. data
About Britannia Life Sciences Inc. (BLAB.CN) Income Statement
Britannia Life Sciences Inc. (BLAB.CN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BLAB.CN reported revenue of $0.00B, gross profit of $0.00B (gross margin 7.40%), and net income of $0.01B — a net profit margin of 2001.95%.
Frequently asked questions
BLAB.CN · 4 questionsBritannia Life Sciences Inc. (BLAB.CN) reported revenue of $0.00B for 2025, down 95.1% year-over-year.
BLAB.CN revenueBLAB.CN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08